TMBIM4 and peripheral neuropathy: Recently, the push for highly selective S1R antagonists as therapeutics for neuropathic pain yielded MR309 (also known as E-52862), an S1R antagonist in phase IIa clinical trials for oxaliplatin-induced peripheral neuropathy [17], and [18F]FTC-146, which completed phase I clinical trials as a highly selective S1R PET imaging agent to visualize nerve damage in neuropathic states [18,19,20,21].